PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Scope & Guideline

Pioneering Research for Tomorrow's Therapeutics

Introduction

Delve into the academic richness of PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0278-5846
PublisherPERGAMON-ELSEVIER SCIENCE LTD
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1982 to 2024
AbbreviationPROG NEURO-PSYCHOPH / Prog. Neuro-Psychopharmacol. Biol. Psychiatry
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND

Aims and Scopes

The journal "Progress in Neuro-Psychopharmacology & Biological Psychiatry" focuses on advancing the understanding of neuropsychopharmacological processes and biological underpinnings of psychiatric disorders. It publishes research that spans across various methodologies and interdisciplinary approaches that integrate neurobiology, psychopharmacology, and psychiatry.
  1. Neurobiological Mechanisms in Psychiatric Disorders:
    The journal emphasizes research that elucidates the neurobiological mechanisms underlying various psychiatric disorders, including depression, schizophrenia, bipolar disorder, and anxiety disorders. This includes studies on neurotransmitter systems, neuroinflammation, and neuroplasticity.
  2. Pharmacological Interventions and Innovations:
    A core focus is on the evaluation and development of pharmacological treatments for mental health disorders, including traditional medications and novel therapeutic approaches such as psychedelics and cannabinoids.
  3. Translational Research:
    The journal promotes translational research that connects basic neuroscience findings with clinical applications, aiming to bridge the gap between laboratory research and practical treatments in psychiatric care.
  4. Psychobiotics and Gut-Brain Axis:
    There is a growing interest in the role of the gut microbiome in mental health, with research exploring how psychobiotics and gut-brain interactions influence psychiatric conditions and treatment outcomes.
  5. Neuroimaging and Biomarkers:
    The use of neuroimaging techniques and biomarkers to understand psychiatric disorders is a significant focus, facilitating the identification of structural and functional brain changes associated with various mental health conditions.
The journal is currently witnessing several trending and emerging themes that reflect the evolving landscape of research in neuropsychopharmacology and biological psychiatry. Here are some notable trends:
  1. Neuroinflammation as a Key Factor:
    There is an increasing body of research focusing on the role of neuroinflammation in psychiatric disorders, highlighting its impact on disease progression and treatment response.
  2. Psychedelic Research:
    Research into the therapeutic potential of psychedelics for various psychiatric conditions is gaining momentum, with studies investigating their mechanisms of action and clinical efficacy.
  3. Precision Medicine and Biomarkers:
    The emphasis on precision medicine is growing, with a focus on identifying biomarkers that can predict treatment responses and personalize interventions for mental health disorders.
  4. Gut-Brain Axis Research:
    Emerging studies on the gut-brain axis are becoming increasingly prevalent, exploring how gut microbiota influence mental health and the implications for treatment strategies involving probiotics.
  5. Machine Learning and AI in Psychiatry:
    The incorporation of machine learning and artificial intelligence in analyzing neuroimaging and clinical data is on the rise, offering new insights into psychiatric disorders and enhancing diagnostic accuracy.

Declining or Waning

While the journal continues to publish a wide range of topics, certain themes appear to be declining in prominence over recent years. Here are some areas that have shown a decrease in focus:
  1. Traditional Psychopharmacology:
    There seems to be a waning emphasis on traditional psychopharmacological studies focusing solely on established medications, as the field shifts towards exploring novel compounds and integrative approaches.
  2. Behavioral Studies without Biological Correlates:
    Research that primarily investigates behavioral aspects of psychiatric disorders without linking them to biological or neurophysiological mechanisms is becoming less frequent, as the journal seeks more integrative studies.
  3. Longitudinal Studies in Non-Clinical Populations:
    There has been a noticeable reduction in the publication of longitudinal studies examining psychiatric symptoms in non-clinical populations, as the focus pivots towards more targeted clinical and translational research.
  4. Single-Causal Pathway Studies:
    Research that explores single-causal pathways for psychiatric disorders is less common now; there is a shift towards understanding complex interactions and multi-factorial models.

Similar Journals

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Pioneering insights in clinical psychiatry and mental health.
Publisher: TAYLOR & FRANCIS LTDISSN: 1365-1501Frequency: 4 issues/year

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE is a distinguished publication in the field of Psychiatry and Mental Health, published by TAYLOR & FRANCIS LTD in the United Kingdom. With an impressive 2023 impact factor that places it in the Q2 category among its peers, this journal is an essential resource for researchers, clinicians, and students dedicated to advancing mental health practices and understanding psychiatric disorders. Covering topics from clinical studies to innovative treatment methodologies, the journal welcomes original research, reviews, and case studies that contribute valuable insights into clinical practice. Accessible without any open access restrictions, the journal has been a pivotal platform since its inception in 1997, facilitating knowledge exchange in the field up to 2024. As evidenced by its notable Scopus ranking within the top 73rd percentile of Psychiatry and Mental Health, it remains committed to impacting clinical practices significantly.

NEUROPSYCHOBIOLOGY

Decoding Behavior: Insights from Neuropsychobiology
Publisher: KARGERISSN: 0302-282XFrequency: 6 issues/year

NEUROPSYCHOBIOLOGY, published by KARGER, is a leading academic journal that has been at the forefront of exploring the intricate relationships between neuroscience and psychological processes since its inception in 1975. With both an ISSN of 0302-282X and an E-ISSN of 1423-0224, the journal is renowned for its rigorous peer-reviewed articles and significant contributions to the fields of Biological Psychiatry, Neuropsychology, and Physiological Psychology. Its impact is reflected in its esteemed Scopus rankings, standing out in the 92nd and 81st percentiles in their respective categories. With a commitment to advancing understanding in mental health and neurological science, NEUROPSYCHOBIOLOGY is classified in the Q3 and Q1 quartiles, making it a vital resource for researchers, clinicians, and students alike. Based in Switzerland, the journal embraces a holistic approach to psychological research, bridging gaps between theoretical frameworks and practical applications, thus promoting impactful advancements in the understanding of the human mind.
Explore the latest findings and theories with NEUROPSYCHOBIOLOGY, where your work can contribute to the evolving landscape of neuropsychological studies.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Pioneering insights into psychiatric disorders and treatments.
Publisher: OXFORD UNIV PRESSISSN: 1461-1457Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

Annals of Indian Psychiatry

Exploring the Frontiers of Mental Health in India
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2588-8358Frequency: 4 issues/year

Annals of Indian Psychiatry is a premier journal dedicated to the field of mental health and psychiatry, published by Wolters Kluwer Medknow Publications. As an Open Access journal since 2017, it provides a platform for disseminating high-quality research articles, clinical studies, and reviews that address the diverse aspects of psychiatric disorders, treatment methodologies, and mental health policy in India and beyond. The journal aims to bridge gaps in the existing literature, support practitioners with evidence-based insights, and foster dialog among researchers in the psychiatric community. With an emphasis on innovative approaches and culturally relevant practices, the Annals of Indian Psychiatry serves as a vital resource for psychiatrists, psychologists, social workers, and students engaged in clinical practice and academic research. Its commitment to improving mental health outcomes in diverse populations makes it a significant contributor to the global discourse on psychiatric health.

Current Behavioral Neuroscience Reports

Unveiling Insights at the Intersection of Mind and Environment
Publisher: SPRINGERNATUREISSN: Frequency: 4 issues/year

Current Behavioral Neuroscience Reports, published by SPRINGERNATURE, stands at the forefront of advancements in the intricate field of behavioral neuroscience. Since its inception in 2014, this journal has steadily garnered attention within academic circles, boasting a commendable ranking among its peers, including a Q3 classification in Behavioral Neuroscience and a Q2 classification in Public Health, Environmental and Occupational Health as of 2023. Although it operates under traditional access models, the journal is committed to disseminating high-quality research that bridges the gap between neuroscience and behavioral studies, appealing to researchers, professionals, and students alike. With a notable E-ISSN of 2196-2979, Current Behavioral Neuroscience Reports facilitates valuable insights that are critical for understanding the underlying mechanisms of behavior and their implications for public health and environmental factors. This journal is essential for those seeking to contribute to a multidisciplinary dialogue that enhances our comprehension of behavioral neuroscience.

PSYCHIATRY RESEARCH-NEUROIMAGING

Pioneering Research at the Intersection of Mind and Machine
Publisher: ELSEVIER IRELAND LTDISSN: 0925-4927Frequency: 12 issues/year

PSYCHIATRY RESEARCH-NEUROIMAGING, published by Elsevier Ireland Ltd, stands at the intersection of neuroscience, psychiatry, and medical imaging, specializing in the latest advancements in neuroimaging techniques and their applications in psychiatric research. With a robust history since 1990, this esteemed journal features original research, reviews, and case studies that contribute significantly to the understanding of brain function in mental health disorders. Holding a notable Impact Factor and classified in Q2 for the fields of Neuroscience and Psychiatry and Q1 for Radiology, it serves as a vital resource for scholars and practitioners seeking to advance their knowledge in these domains. The journal is indexed in major databases, enhancing visibility and accessibility for global researchers. While it currently does not follow an open-access model, its reputable standing in Scopus ranks, alongside its targeted scope, makes it indispensable for those invested in neuroimaging research and its implications in psychiatry.

PSYCHIATRY RESEARCH

Connecting research to real-world psychiatric care.
Publisher: ELSEVIER IRELAND LTDISSN: 0165-1781Frequency: 12 issues/year

PSYCHIATRY RESEARCH is a leading journal published by Elsevier Ireland Ltd, dedicated to advancing the field of psychiatry and mental health through the dissemination of rigorous research. With an impressive impact factor and categorized in the top quartile (Q1) of both Biological Psychiatry and Psychiatry and Mental Health in 2023, this journal ranks 14th in the field of Medicine _ Psychiatry and Mental Health out of 567 journals, and 4th in Neuroscience _ Biological Psychiatry out of 51, showcasing its influence and quality. Since its inception in 1979, PSYCHIATRY RESEARCH has provided a platform for innovative studies, clinical trials, and comprehensive reviews aimed at understanding the complexities of mental health disorders. Although it operates under a traditional access model, the journal remains committed to making vital research available to the academic community, ensuring that both seasoned professionals and budding researchers have access to groundbreaking findings. Positioned as a hub for psychiatric research, it caters to a diverse audience including clinicians, psychologists, and students, empowering them to contribute to the evolving landscape of mental health care.

Neuropsychopharmacology Reports

Fostering collaboration in the realm of mental health and pharmacology.
Publisher: WILEYISSN: Frequency: 4 issues/year

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

Biological Psychiatry

Integrating biology and clinical perspectives for groundbreaking discoveries.
Publisher: ELSEVIER SCIENCE INCISSN: 0006-3223Frequency: 24 issues/year

Biological Psychiatry is a premier journal dedicated to advancing the understanding of the biological underpinnings of psychiatric disorders. Published by Elsevier Science Inc, this esteemed journal is recognized globally for its rigorous peer-reviewed research and contributes significantly to the field of biological psychiatry. With an impressive impact factor that places it in Q1 of its category and ranks 3rd out of 51 in Neuroscience Biological Psychiatry, it reflects the journal's strength in disseminating high-quality findings that push the boundaries of knowledge. Since its inception in 1969, the journal has undergone continuous evolution, aiming to integrate biological and clinical perspectives to optimize the understanding of mental health conditions. Although it does not offer open access, Biological Psychiatry serves as a critical resource for researchers, practitioners, and students, offering insights that influence both theoretical frameworks and practical applications in the realm of psychiatric science.

Translational Psychiatry

Fostering collaboration for a brighter future in mental health.
Publisher: SPRINGERNATUREISSN: 2158-3188Frequency: 1 issue/year

Translational Psychiatry, an esteemed journal published by SpringerNature, is at the forefront of research in the fields of biological psychiatry, neuroscience, and mental health. With an impressive Q1 category ranking in Biological Psychiatry, Cellular and Molecular Neuroscience, and Psychiatry and Mental Health, the journal fosters high-quality scholarly work that informs clinical practices and guides future research directions. Since its inception in 2011, Translational Psychiatry has embraced the Open Access model, ensuring that groundbreaking findings are easily accessible to all, promoting collaboration and innovation within the global scientific community. With a solid ranking in Scopus—particularly at #33 out of 567 in Psychiatry and Mental Health and #6 out of 51 in Biological Psychiatry—this journal plays a critical role in advancing our understanding of mental health disorders, bridging the gap between bench science and clinical application. As it continues evolving through its converged years from 2011 to 2024, Translational Psychiatry remains an essential resource for researchers, healthcare professionals, and students dedicated to improving mental health outcomes.